Actively Recruiting
Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability
Led by University Hospital, Rouen · Updated on 2026-02-20
60
Participants Needed
4
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high. One of the functional abnormalities described during IBS is increased intestinal permeability. This increase in intestinal permeability is primarily present in the diarrheal subtype (IBS-D) and can be measured using the lactulose/mannitol test. Glutamine is a non-essential amino acid which regulates numerous metabolic pathways, and which plays a key role in the intestine because it is the preferential substrate of enterocytes and immune cells. Ex vivo, glutamine is able to restore the expression of tight junction proteins in patients suffering from IBS-D. On the other hand, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a subgroup of patients with intestinal permeability disorder (post-infectious IBS-D). The working hypothesis would be that all patients suffering from IBS with permeability disorder, measured by the lactulose/mannitol test, could benefit from oral glutamine supplementation.
CONDITIONS
Official Title
Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult aged 18 to 75
- Diagnosed with diarrheal irritable bowel syndrome (IBS-D) according to Rome IV criteria
- Francis score greater than 175 out of 500 at inclusion indicating moderate to severe IBS
- Stable IBS treatments for more than 1 month
- Affiliated with a social security system
- Able to read, understand the information, and sign the consent form
- Women of childbearing age must use effective contraception for at least 1 month and have a negative urine pregnancy test
- Postmenopausal women must have confirmed diagnosis with at least 12 months of natural amenorrhea or biological confirmation
You will not qualify if you...
- Use of probiotics, anti-inflammatories, corticosteroids, or antibiotics within 1 month before or during the study
- Known active autoimmune diseases such as type 1 diabetes, lupus, multiple sclerosis, thyroiditis, ankylosing spondylitis, rheumatoid arthritis, or psoriasis
- Known allergy to glutamine
- Contraindications to glutamine, protein powder, lactulose, or mannitol (including sugar-free chewing gum)
- Use of osmotic laxatives, lactulose, or protein supplements including glutamine within 4 weeks before study start
- Renal insufficiency with GFR less than 40 mL/min, hepatic insufficiency with PT less than 70, or known heart disease
- History of digestive diseases like celiac disease, chronic inflammatory bowel disease, or abdominal surgery other than appendectomy or cholecystectomy
- Presence of occlusive or subocclusive syndrome
- Digestive perforation or suspicion of perforation
- Abdominal pain syndrome without known cause
- Chronic alcohol consumption over 14 units per week
- Pregnancy, breastfeeding, or lack of effective contraception
- Legal restrictions such as being deprived of liberty or under judicial protection
- Participation in another clinical trial within the last 2 weeks
- Psychological, sensory, or illness history that prevents understanding or consenting to study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Chu Amiens
Amiens, France, 80054
Not Yet Recruiting
2
CHU CAEN
Caen, France, 14033
Actively Recruiting
3
Ch Le Havre
Le Havre, France, 76290
Actively Recruiting
4
Chu Rouen
Rouen, France, 76031
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here